• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

search results for: dealforma

Af­ter a slate of small, tack-on ac­qui­si­tions, is Mer­ck ready to pull the trig­ger on a big M&A deal?

7 years ago
Pharma

By the num­bers: Top M&A deals, VC in­vest­ments and pacts point to a grow­ing hunger for gene ther­a­py deals

7 years ago
Pharma
Cell/Gene Tx

Roche joins the M&A game, buy­ing gene ther­a­py pi­o­neer Spark for $4.3B

7 years ago
Deals
Cell/Gene Tx

The $100M biotech club: Who's in, and what’s it take to join the top-per­form­ing group of bio­phar­mas?

7 years ago
Pharma

The high rollers: The top 20 block­buster bio­phar­ma deals of the past decade

7 years ago
Pharma

Top 20 biotech deals: 2019 deal­mak­ing gets off to a roar­ing start, build­ing on a record amount for '18

7 years ago
Pharma

By the num­bers for 2018: The top 100 ven­ture play­ers in biotech — and who's been pay­ing the piper in can­cer R&D?

7 years ago
Financing

Scoop: GSK’s ven­ture team at SR One in talks to spin off from its big phar­ma founder, now un­der new R&D man­age­ment

7 years ago
Financing
Pharma

Cel­gene's top 20 up­front hits: Just how gen­er­ous was Cel­gene in deal­mak­ing? Let's re­view the records

7 years ago
Pharma

The high-roller club in bio­phar­ma: Who’s pay­ing top-dol­lar for up­fronts? And who are the busiest play­ers at the ...

7 years ago
R&D
Pharma
First page Previous page 4567

latest

Most read

Bio­phar­ma's 20 high­est-paid CEOs of 2024 with $20M+ pay­days

4 days ago
People
Pharma

Bio­phar­ma’s high­est-paid CEOs; John Car­roll’s Q2 analy­sis; Mer­ck to buy Verona Phar­ma for $10B; and more

22 hours ago
Weekly

Karyopharm cuts 20% of staff as it looks at 's­trate­gic al­ter­na­tives' or rais­ing cash

Yesterday
Financing

Eu­ro­pean reg­u­la­tors lift re­stric­tion on Val­ne­va’s chikun­gun­ya vac­cine

Yesterday
Pharma
FDA+

No­var­tis dealt a blow in patent fight to block En­tresto gener­ics

Yesterday
Pharma
Law
see latest stream
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times